Recursion Pharmaceuticals Statistics
Total Valuation
RXRX has a market cap or net worth of $1.76 billion. The enterprise value is $1.35 billion.
Important Dates
The last earnings date was Monday, May 5, 2025, before market open.
Earnings Date | May 5, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
RXRX has 406.92 million shares outstanding. The number of shares has increased by 44.28% in one year.
Current Share Class | 399.66M |
Shares Outstanding | 406.92M |
Shares Change (YoY) | +44.28% |
Shares Change (QoQ) | +19.86% |
Owned by Insiders (%) | 4.65% |
Owned by Institutions (%) | 73.49% |
Float | 387.56M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 22.88 |
Forward PS | 30.08 |
PB Ratio | 1.88 |
P/TBV Ratio | 4.00 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 22.65 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.11, with a Debt / Equity ratio of 0.10.
Current Ratio | 4.11 |
Quick Ratio | 3.85 |
Debt / Equity | 0.10 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -278.66 |
Financial Efficiency
Return on equity (ROE) is -86.10% and return on invested capital (ROIC) is -48.52%.
Return on Equity (ROE) | -86.10% |
Return on Assets (ROA) | -38.51% |
Return on Invested Capital (ROIC) | -48.52% |
Return on Capital Employed (ROCE) | -49.35% |
Revenue Per Employee | $74,738 |
Profits Per Employee | -$718,469 |
Employee Count | 800 |
Asset Turnover | 0.06 |
Inventory Turnover | n/a |
Taxes
Income Tax | -506,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.59% in the last 52 weeks. The beta is 0.98, so RXRX's price volatility has been similar to the market average.
Beta (5Y) | 0.98 |
52-Week Price Change | -49.59% |
50-Day Moving Average | 5.66 |
200-Day Moving Average | 6.72 |
Relative Strength Index (RSI) | 36.38 |
Average Volume (20 Days) | 22,296,127 |
Short Selling Information
The latest short interest is 94.52 million, so 23.23% of the outstanding shares have been sold short.
Short Interest | 94.52M |
Short Previous Month | 88.50M |
Short % of Shares Out | 23.23% |
Short % of Float | 24.39% |
Short Ratio (days to cover) | 4.10 |
Income Statement
In the last 12 months, RXRX had revenue of $59.79 million and -$574.78 million in losses. Loss per share was -$1.82.
Revenue | 59.79M |
Gross Profit | -372.61M |
Operating Income | -574.03M |
Pretax Income | n/a |
Net Income | -574.78M |
EBITDA | -525.58M |
EBIT | -574.03M |
Loss Per Share | -$1.82 |
Full Income Statement Balance Sheet
The company has $500.45 million in cash and $92.91 million in debt, giving a net cash position of $407.54 million or $1.00 per share.
Cash & Cash Equivalents | 500.45M |
Total Debt | 92.91M |
Net Cash | 407.54M |
Net Cash Per Share | $1.00 |
Equity (Book Value) | 933.95M |
Book Value Per Share | 2.30 |
Working Capital | 442.16M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$388.83 million and capital expenditures -$8.87 million, giving a free cash flow of -$397.71 million.
Operating Cash Flow | -388.83M |
Capital Expenditures | -8.87M |
Free Cash Flow | -397.71M |
FCF Per Share | -$0.98 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | -960.08% |
Pretax Margin | -962.17% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
RXRX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -44.28% |
Shareholder Yield | n/a |
Earnings Yield | -32.62% |
FCF Yield | -22.57% |
Dividend Details Analyst Forecast
The average price target for RXRX is $7.60, which is 75.52% higher than the current price. The consensus rating is "Buy".
Price Target | $7.60 |
Price Target Difference | 75.52% |
Analyst Consensus | Buy |
Analyst Count | 5 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
RXRX has an Altman Z-Score of 0.86 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 0.86 |
Piotroski F-Score | 1 |